ASX Healthcare Stocks Strengthening Bullish Momentum

Several ASX healthcare stocks which are focused on unmet medical needs are drawing renewed interest as advancing clinical progress and upcoming catalysts create opportunities for investors who want exposure to this sector.

Prescient Therapeutics Limited (ASX: PTX)

on 15 December announced that the European Clinical Trials Information System has granted authorisation to begin its PTX-100 clinical trial in patients with relapsed and refractory Cutaneous T-cell Lymphoma (CTCL) in Italy.

This approval enables Prescient to activate European trial sites and start patient recruitment for the Phase 2a study while the company ended the quarter with cash reserves of $12.3 million compared to $6.9 million as of 30 June 2025.

Net operating cash outflow for the September quarter was $4.1 million with $2.8 million directed towards R&D and clinical activities.

There are currently seven active clinical trial sites operating across Australia and United States and two additional sites are expected to be opened in the upcoming quarter.

PYC Therapeutics Limited (ASX: PYC)

is focused on its lead drug candidate PYC-003 which targets the underlying cause of Polycystic Kidney Disease (PKD) and is being evaluated through clinical trials.

The company recently announced that dosing has been escalated to the second cohort in Part B of the Single Ascending Dose study which is being conducted in PKD patients.

As of 30 September 2025, the company held $135 million in cash with a further $20 million expected to be received in Q1 2026 because of FY25 R&D rebate.

The company expects multiple human safety and efficacy readouts across the pipeline from late 2025 through 2027 while continuing discussions with regulators.

Argenica Therapeutics Limited (ASX: AGN)

is a clinical stage biotechnology company which is focused on developing neuroprotective therapies designed to reduce brain tissue death following stroke and other forms of brain injury with ARG-007 positioned as the company’s lead asset.

Recently ARG-007 showed statistically significant improvements in follow up infarct volume and functional outcomes in patients with more severe strokes when stroke severity scoring was standardised using an FDA approved AI tool.

AGN closed the quarter with cash reserves of $6.4 million which provides funding support for its development activities.

The company is advancing preparations for a Phase 2b trial which could act as a key catalyst as the program progresses towards later stage development.

Actinogen Medical Limited (ASX: ACW)

is a biotechnology company advancing its oral drug Xanamem which targets brain cortisol and is being developed for Alzheimer’s disease and major depressive disorder.

During FY25, the company achieved an important development milestone as the pivotal XanaMIA Phase 2b/3 Alzheimer’s disease trial surpassed 100 enrolled patients with interim safety and efficacy analysis scheduled for January 2026 and final results expected in late 2026.
The company finished the year with cash of $16.5 million which provides a funding cushion to support ongoing clinical development activities.

The company is focused on the January 2026 interim data readout from the XanaMIA trial and progress on partnership discussions could act as key value catalysts as ACW moves closer to commercialisation.

(Source: Company Reports)